Skip to main content
. 2017 Aug 17;3(3):00004-2017. doi: 10.1183/23120541.00004-2017

FIGURE 2.

FIGURE 2

Effects of reslizumab on lung function (forced expiratory volume in 1 s; FEV1) in Global Initiative for Asthma (GINA) Step 4 and 5 patients. (a) Changes from baseline FEV1 at week 16 and week 52 and (b) changes relative to placebo throughout the study. LS: least square.